Charles Schwab Investment Management Inc. Grows Stock Holdings in AxoGen, Inc. (NASDAQ:AXGN)

Charles Schwab Investment Management Inc. increased its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) by 8.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 363,764 shares of the medical equipment provider’s stock after purchasing an additional 28,659 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.83% of AxoGen worth $5,100,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Quest Partners LLC raised its holdings in shares of AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 2,076 shares during the last quarter. nVerses Capital LLC purchased a new stake in AxoGen during the third quarter valued at approximately $56,000. Koss Olinger Consulting LLC purchased a new stake in AxoGen during the second quarter valued at approximately $75,000. Oppenheimer & Co. Inc. purchased a new stake in AxoGen during the third quarter valued at approximately $156,000. Finally, Intech Investment Management LLC purchased a new stake in AxoGen during the third quarter valued at approximately $173,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, AxoGen has a consensus rating of “Buy” and a consensus price target of $15.00.

AxoGen Stock Performance

AXGN opened at $14.41 on Friday. The firm has a market cap of $634.16 million, a P/E ratio of -45.03 and a beta of 1.06. AxoGen, Inc. has a 1-year low of $5.55 and a 1-year high of $15.90. The company has a 50 day simple moving average of $13.81 and a two-hundred day simple moving average of $11.38. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.